The Syneos Health Podcast

How can we use technology and increasing volumes of data to change the future of human health and healthcare as we move forward into 2023 and beyond?  In this episode of the limited Trend Talks series, Leigh Householder, Host & Author, 2023 Health Trends: Personally, Purposefully Building What’s Next , sits down with  Bob Zambon , VP, Solution Architecture Group, Syneos Health, to discuss how...

How will a new field for the field force keep the doors open for customer communication while considering differences in culture, therapy, product lifecycle stage and healthcare professional preference? In this episode of the limited Trend Talks series, Leigh Householder, Host & Author, 2023 Health Trends: Personally, Purposefully Building What’s Next , sits down with Ewan Cuthbertson , SVP, E...

How will Digital transformation continue to impact the healthcare industry and help drive automation, efficiencies, quality and other changes to how we engage and operate in the future? In this episode of the limited Trend Talks series, Leigh Householder, Host & Author, 2023 Health Trends: Personally, Purposefully Building What’s Next , sits down with Skye Hodson , PhD, Senior Director, Produc...

Last year the FDA approved the first gene therapy for hemophilia B . This year, the first gene therapy may be approved in the US for hemophilia A. What does the gene therapy revolution mean for patients, payers, and pharma?   Ankita Chowdhury , Senior Engagement Manager, Commercial Advisory at Syneos Health®, joins the podcast to discuss the landscape of recent hemophilia gene therapy approvals, t...

The Inflation Reduction Act of 2022 is a landmark United States federal law which aims to curb inflation by, among other things, lowering prescription drug prices. What can this mean for biopharmaceutical companies? Dennis Kim, Senior Engagement Manager and Em Coriale , Director in the Value & Access team at Syneos Health, dive into the details of this piece of legislation, the true meaning of...

How will Artificial Intelligence continue to impact the healthcare industry and its potential to introduce new technologies, enabling a shift from promise to performance?   In this episode of the limited Trend Talks series, Leigh Householder Host & Author, 2023 Health Trends: Personally, Purposefully Building What’s Next , sits down with Andrew Barron , SVP of Global Site Start Up & Regula...

 In this episode of the limited Trend Talks series, Leigh Householder Host & Author, 2023 Health Trends: Personally, Purposefully Building What’s Next , sits down with James Ian , a Musician and Actor who lives with Spinal Muscular Atrophy Type Three—a rare neuromuscular disease that attacks the neurons that control all the voluntary muscles in the body. James is a passionate advocate for disa...

This new podcast mini-series features interviews with industry leaders, focusing on hot topics within Regulatory Operations (Reg Ops). Reg Ops is evolving in response to a rapidly changing regulatory landscape as well as the industry’s focus on achieving operational efficiency and excellence. Technological innovations such as advancements in Regulatory Information Management (RIM) capabilities are...

It’s a volatile time for biopharma, and a unique juncture in our industry’s history. War in Ukraine, a bearish market and supply chain chaos are just a few of the factors that kept much of the industry away from the table. Entering 2023, the investment and dealmaking panorama remains a puzzle. Despite worries and uncertainties, there are hints that dealmaking intensity may be poised for a rebound...

What’s Changed, What’s Changing and What Matters Most Right Now In this inaugural episode of the limited podcast series on 2023 Health Trends, we’re setting the stage with Host & Author, 2023 Health Trends: Personally, Purposefully Building What’s Next , Leigh Householder.  Leigh provides a high-level look at what will be different this year. First, she discusses urgent optimism and the person...

When it comes to the generation and use of real-world data (RWD), there are variable and evolving stakeholder needs. Put it in the context of a rare disease, where patient samples are decreasing as diseases splinter with increasing specificity in diagnosis, and the prospect of meeting these stakeholder needs becomes more daunting. Layer on special circumstances—like a required 15 years of post-app...

Common misconceptions surrounding decentralized research often deter sponsors from attaining its key benefits—and this is especially true for small or emerging biotechs with limited shots on goal.  But by separating fact from fiction and understanding how to identify fit for purpose solutions, these companies can lay the roadmap for successful implementation of a decentralized clinical trial (DCT)...

Early stage biotech companies have traditionally had limited options to get their first asset to market: in most cases, they pursue deals with larger partners, losing control of their intellectual property and limiting their future financial returns, or become a fully integrated company through heavy investment and a great deal of risk.  Opportunities for outsourcing some—or all—of a company’s com...

This podcast series features interviews with industry leaders, focusing in on the impact and value of Medical Affairs today, where the function is heading and how we are going to get there.  Today we are speaking with Dr. Kirk Shepard , co-founder of the Medical Affairs Professional Society (MAPS) and Chief Medical Officer and Head of Global Medical Affairs at Eisai. Dr. Shepard has effectively br...

This podcast series features interviews with industry leaders, focusing in on the impact and value of Medical Affairs today, where the function is heading and how we are going to get there.  In this continuation from our previous episode, Colin Oliver, PhD, MBA , Managing Director, Medical Affairs Consulting at Syneos Health, steps in as guest host to dig in more deeply with Eisai’s Dr. Kirk Shepa...

Cell and gene therapies have come a long way in the past 20 years. And more recent advances and successes with CRISPR and CAR-T technologies have left the field of opportunity wide open for treatments that can potentially move the needle, particularly for patients with oncologic or rare diseases. But with great advancements come significant challenges. Pete Robinson , Vice President, Medical and S...

Reporting from the floor of the Medical Affairs Professionals Society (MAPS) Global Annual Meeting, this podcast series features interviews with industry leaders, focusing in on the impact and value of Medical Affairs today, where the function is heading and how we are going to get there.  As Medical Affairs has evolved, so have the acumen required for Medical Affairs professionals and leaders to...

Reporting from the floor of the Medical Affairs Professionals Society (MAPS) Global Annual Meeting, this podcast series features interviews with industry leaders, focusing in on the impact and value of Medical Affairs today, where the function is heading and how we are going to get there.  There’s been an overall shift in the healthcare ecosystem toward more proactive and cross-functional engageme...

Reporting from the floor of the Medical Affairs Professionals Society (MAPS) Global Annual Meeting, this podcast series features interviews with industry leaders, focusing in on the impact and value of Medical Affairs today, where the function is heading and how we are going to get there. It’s no question that Medical Affairs has historically struggled to show value and impact within its organizat...

Reporting from the floor of the Medical Affairs Professionals Society (MAPS) Global Annual Meeting, this podcast series features interviews with industry leaders, focusing in on the impact and value of Medical Affairs today, where the function is heading and how we are going to get there. As a function uniquely positioned to address evolving market dynamics, how can Medical Affairs prepare for 203...

The clinical research enterprise faces a clear and present personnel shortage, creating inefficiencies for clinical trial sponsors and contract research organizations, many of whom find themselves in a constant recruitment cycle for qualified clinical research associates (CRAs) in a hyper-competitive job market.  While industry has traditionally recruited for these roles from healthcare and scient...

The medicine may be “transformational,” but doctors won’t write the script if payers don’t reimburse. And there’s a veritable alphabet soup of players – everything from KAMs to NAMs, MSLs to MSOLs, PBMs to IDNs, and more – involved in negotiating the path to reimbursement and, ultimately, access for innovative therapies when they hit the market.  Jon Haas , Senior Director, Market Access at Syneos...

Nobody thinks about epilepsy as a rare disease. But epilepsy syndromes actually make up a large portion of CNS rare diseases. And while progress has been made in developing therapies that treat the symptoms of epilepsy, the true underlying causes can be difficult to pinpoint and treat.  But progress is being made, and Nermina Nakas, MD, MPH and Jane Williams, MD, MPH , Executive Medical Directors...

Did you know that over half of doctors leverage the placebo effect in treating patients? Placebo can be a powerful tool in medical practice—and in clinical research. Veeru Goli, MD , Vice President, Medical and Scientific Management, Syneos Health, unpacks the case for use of placebo in clinical treatment, and if applied properly, how the placebo effect can help in clinical trials. If you want acc...

Life with a rare disease can have infinite milestones, setbacks, traumas and triumphs—all likely to be interlaced with a variety of factors that can influence mental health and quality of life. In fact, according to Dr. Raymond A. Huml in the February 2020  Journal for Clinical Studies,  psychological symptoms are estimated to affect 75% of rare disease patients. Whether the cause is from the phys...